Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Официальное название

Clinical Study on Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Обзор

The goal of this clinical trial is to test the effect of the administration of APPORTAL® in addition to the SoC (recommended physical exercise), in patients with breast cancer, suffering from fatigue during neoadjuvant and adjuvant chemotherapy. The main questions it aims to answer are: * if the food supplement APPORTAL® can be of help in supporting the physiological energy level, against the fatigue symptom in cancer patients undergoing adjuvant chemotherapy; * if the supplementation with APPORTAL® can optimize the nutritional status, the muscular strength, the quality of life of the patient. Also, the patients' satisfaction on the product received, the adherence to treatment will be evaluated and the overall safety and tolerability of the study product. The patients will be asked to perform 3 study visits from baseline to the end of treatment (at 4 and 8 weeks after baseline) and a follow-up visit after 12 weeks from baseline. The main assessments at each visit will be: * physical examination, weight, Body Mass Index (BMI), body temperature (°C), heart rate, respiratory frequency, and systolic and diastolic blood pressure; * previous and concomitant treatments; * fatigue assessment through BFI questionnaire; * quality of life through questionnaire SF-12; * muscular strength (dynamometer) * Adverse Event check (from Visit 2) Moreover, at visit 1 (baseline) and at visit 3 (end of treatment) a blood sample will be collected to evaluate the blood metabolites. Telephonic follow-up will be done at 2 weeks, 6 weeks, 10 weeks to assess compliance and to recommendations on physical activity and to study treatment (only at 2 and 6 weeks) and tolerability/safety. Participants will receive the nutrition supplement or the placebo, in addition to the SoC (recommended physical exercise), for 8 weeks. Researchers will compare Apportal® and Placebo groups to see if the physiological energy level against the fatigue symptom, the nutritional status, the muscular strength, the quality of life of the patient improve after 8 weeks of treatment with APPORTAL® in addition to SoC (recommended physical exercise).

Подробное описание

SAMPLE SIZE DETERMINATION Considering the average of the BFI 5 in the placebo group and the average 3 in the treated group, with standard deviation of 3, power at 80% and alpha 0.05, we obtain 37 patients per group, thus a total of 74 patients. If a drop-out rate of 20% is fixed, 92 patients in total are obtained. So, a sample of 92 subjects would be sufficient.

DATA SAFETY MONITORING BOARD / DATA MONITORING COMMITTEE No Data Safety Monitoring Board (DSMB) or Data Monitoring Committee (DMC) will be convened for the evaluation of safety data during the study. However, the Network Italiano Cure di Supporto in Oncologia (NICSO) society will be in charge of the evaluation of safety information. In fact, a Scientific Committee, composed by NICSO members, has been established to support the Sponsor in the continuous evaluation of safety data emerging from the study.

MONITORING AND QUALITY ASSURANCE The study will be monitored by adequately qualified and trained clinical monitors. Before the start of the study, the CRO (Contract Research Organization) responsible for the study site has the task to assess the adequacy of the study site and the staff involved. After start, the study will be monitored to ensure the proper conduct of the clinical study.

DATA COLLECTION An Electronic Case Report Form (e-CRF) will be used for recording patient's study data.

The Investigator will maintain a list of all persons authorized to make entries and/or corrections on the CRFs. Each authorized person will be provided with a user-specific ID (Identification) protected by a renewable password. Data entries and corrections will be made only by the authorized persons. The e-CRF system will record date and time of any entry and /or correction and the user ID of the person making the entry/correction. The system will keep track of all old and new values (audit trail).

Вмешательства

• Пищевая добавка APPOPRTAL®
  1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
• Другое Placebo
  Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene

Первичные конечные точки

• The change of fatigue perception by the patient through the BFI questionnaire [Срок оценки: Change from baseline to 8 weeks of treatment (Visit 3), in active and placebo groups.]

Вторичные конечные точки (12)

• The change of fatigue perception by the patient through the BFI questionnaire [Срок оценки: Change after 4, 8 and 12 weeks with respect to baseline in both the active and placebo groups]
• Change in Iron status through hemoglobin assessment [Срок оценки: Change after 8 weeks of study treatment with respect to baseline, in both the active and placebo groups]
• Change in Iron status through ferritin assessment [Срок оценки: Change after 8 weeks of study treatment with respect to baseline, in both the active and placebo groups]
• Change in Iron status through transferrin saturation assessment [Срок оценки: Change after 8 weeks of study treatment with respect to baseline in both the active and placebo groups]
• Change in nutritional status through albumin assessment [Срок оценки: Change after 8 weeks of study treatment with respect to baseline in both the active and placebo groups]
• Change in nutritional status through assessment of total cholesterol, HDL, LDL and triglycerides [Срок оценки: Change after 8 weeks of study treatment with respect to baseline in both the active and placebo groups]
• Change in oxidative status through homocysteine assessment [Срок оценки: Change after 8 weeks of study treatment with respect to baseline in both the active and placebo groups]
• Change in oxidative status through uric acid assessment [Срок оценки: Change after 8 weeks of study treatment with respect to baseline in both the active and placebo groups]
• Change in oxidative status through C-Reactive Protein (CRP) assessment [Срок оценки: Change after 8 weeks of study treatment with respect to baseline in CRP in both the active and placebo groups]
• Change in serum L-arginina levels [Срок оценки: Change after 8 weeks of study treatment with respect to baseline in both the active and placebo groups]
• Changes in QoL through SF-12 Questionnaire [Срок оценки: Change after 4, 8 and 12 weeks with respect to baseline in both the active and placebo groups]
• Change in muscular strength (hand grip test), [Срок оценки: Change after 4, 8 and 12 weeks with respect to baseline in both the active and placebo groups]

Критерии участия

Критерии включения

• Females aged 18 or higher.
• Patients diagnosed with histologically confirmed breast cancer.
• Patients having done at least one cycle of neoadjuvant or adjuvant chemotherapy (independently from type of chemotherapy) and who are on active chemotherapy treatment throughout the duration of the study (\*).
• Patients with ECOG performance status ≤1 at screening.
• Patients with cancer related fatigue of moderate-severe intensity (Numerical Rating Scale NRS > 4).
• Patients able to follow the recommendations on the physical exercise to do.
• Patients who accept to use adequate contraceptive methods, if they are of child-bearing potential.
• Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures.

(\*)Examples of chemotheraphy and standard therapeutic regimens in the neoadjuvant and adjuvant phase in breast cancer and on the basis of the biological characteristics of the neoplasm are as follows:

Neoadjuvant Chemotheraphy

• Epirubicin + Cyclophosphamide, 3 cycles -> Taxol\* weekly for 12 weeks;
• Epirubicin + Cyclophosphamide -> Pertuzumab + Trastuzumab (or Phesgo) 3 cycles + Taxol weekly for 12 weeks;
• Carboplatin + Taxol\* weekly for 12 weeks -> Epirubicin + Cyclophosphamide;

• Taxol could be replaced by Taxotere

Adjuvant Chemotheraphy

• Epirubicin + Cyclophosphamide, 4 cycles, every 21 days -> Taxol weekly for 12 weeks
• Epirubicin + Cyclophosphamide, 4 cycles, every 14 days -> Taxol, 4 cycles every 14 days
• Epirubicin + Cyclophosphamide, 4 cycles every 21 days -> Taxol weekly + Trastuzumab with or without Pertuzumab for 1 year
• Taxotere + Cyclophosphamide, 4 cycles, every 21 days.

These lists are not to be considered exclusive

Критерии исключения

• Women who are pregnant or breast-feeding.
• Neoplastic disease other than primary breast cancer.
• Had major surgery other than breast cancer surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patients must be well recovered from acute effects of surgery prior to screening. Patients should not have plans to undergo major surgical procedures during the treatment period.
• Patients with known or symptomatic metastases.
• Patients unable to readily swallow. Patients with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption, or obstructive symptoms) or intractable or frequent vomiting are excluded.
• Patients with known or suspected allergy or hypersensitivity to the study products or any of their excipients.
• Patients with an active, uncontrolled infection.
• Patients with uncontrolled diabetes mellitus.
• Patients with untreated clinically relevant hypothyroidism.
• Patients with concomitant not-correctable alterations, present before chemotherapy, possible determinants of fatigue (NRS ≥ 4), such as anemia, not well controlled pain (NRS > 4), insomnia, electrolyte imbalance, dehydration, anorexia/cachexia, hepatic, renal or heart failure, adrenocortical failure, neurological deficit.
• Other clinical diagnosis, serious chronic diseases (renal failure with creatinine clearance <30 ml / min; liver failure, heart failure with NYHA -New York Heart Association- class> 2), ongoing or intercurrent illness that in the Investigator's opinion would prevent the patient's participation.
• Patients receiving opioids or corticosteroids (except as replacement therapy at physiological dose, in subjects with adrenal insufficiency or to prevent emesis on the chemotherapy day).
• Patients receiving parenteral nutrition (either total or partial).
• Use of other investigational drug(s) within 30 days before study entry or during the study.
• Triple negative patients in neoadjuvant treatment with Pembrolizumab.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Тройное слепое

Основная цель

Поддерживающая терапия

Центры проведения

Италия · 5 центров

• U.O.C. Oncologia medica ASST Spedali Civili di Brescia — Brescia
• Cancer Center U.O. Oncologia Medica ed Ematologia IRCCS Humanitas Research Hospital — Rozzano
• U.O. Oncologia 2 Universitaria A.O.U. Pisana — Pisa
• UOSD di Medicina di Precisione e Senologia, Policlinico Universitario A. Gemelli — Rome
• Dipartimento di Oncologia Azienda Sanitaria Universitaria Integrata di Udine — Udine

Публикации

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. PMID 21296855
• Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907. doi: 10.1158/1055-9965.EPI-10-0437. Epub 2010 Jul 20. PMID 20647400
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4. PMID 22237781
• Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS. Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw. 2010 Dec;8(12):1331-9. doi: 10.6004/jnccn.2010.0101. PMID 21147900
• Ruiz-Casado A, Alvarez-Bustos A, de Pedro CG, Mendez-Otero M, Romero-Elias M. Cancer-related Fatigue in Breast Cancer Survivors: A Review. Clin Breast Cancer. 2021 Feb;21(1):10-25. doi: 10.1016/j.clbc.2020.07.011. Epub 2020 Jul 24. PMID 32819836
• So WK, Marsh G, Ling WM, Leung FY, Lo JC, Yeung M, Li GK. The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. Oncol Nurs Forum. 2009 Jul;36(4):E205-14. doi: 10.1188/09.ONF.E205-E214. PMID 19581224
• Gaston-Johansson F, Fall-Dickson JM, Bakos AB, Kennedy MJ. Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Pract. 1999 Sep-Oct;7(5):240-7. doi: 10.1046/j.1523-5394.1999.75008.x. PMID 10687593
• Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. NCCN Clinical Practice Guidelines Cancer-related fatigue. J Natl Compr Canc Netw. 2010 Aug;8(8):904-31. doi: 10.6004/jnccn.2010.0067. No abstract available. PMID 20870636

Идентификаторы

NCT: NCT06137833 · APPORTAL-01-23

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗